ABL Bio Overview

  • Founded
  • 2016
Founded
  • Status
  • Public
  • Employees
  • 90
Employees
  • Stock Symbol
  • 298380
Stock Symbol
  • Share Price
  • $22.63
  • (As of Monday Closing)

ABL Bio General Information

Description

ABL Bio Inc is a Korean biotech research company. The company is engaged in the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline products include ABL001 an Bispecific Antibody, ABL201-205 an Antibody Drug Conjugate, T cell engager, Dual Immune Cell Targeting BsAb an Immuno-Oncology, ABL301 an BBB-Penetrating Bispecific Antibody.

Contact Information

Website
www.ablbio.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
KRX
Primary Office
  • 2F, 16 Daewangpangyo-Ro 712 Beon-Gil
  • Bundang-Gu
  • Seongnam, Gyeonggi-Do 13488
  • South Korea
+82 00000000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

ABL Bio Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$22.63 $24.36 $14.88 - $29.18 $1.07B 47.1M 1.79M -$0.77

ABL Bio Financials Summary

In Thousands,
USD 		TTM 30-Sep-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 710,956 1,255,237 830,137 658,889
Revenue 8,875 6,864 3,421 1,144
EBITDA (34,152) (45,598) (31,475) (105,611)
Net Income (36,000) (47,096) (31,734) (106,663)
Total Assets 64,315 91,569 123,368 151,004
Total Debt 674 1,371 1,624 69
Public Fundamental Data provided by Morningstar, Inc. disclaimer

ABL Bio Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore ABL Bio‘s full profile, request access.

Request a free trial

ABL Bio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
ABL Bio Inc is a Korean biotech research company. The company is engaged in the development of therapeutic drugs for imm
Biotechnology
Seongnam, South Korea
90 As of 2021
00000
0000 0000-00-00
00000000 00000

00 00000

ostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor i
0000000000000
Durham, NC
000 As of 0000
00000
000000 - 000 00000

000000 0

sectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim
000000000000000
Foster City, CA
00000 As of 0000
00.000
000000000 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ABL Bio Competitors (7)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
G1 Therapeutics Formerly VC-backed Durham, NC 000 00000 000000 - 000 00000
000000 00000000 Formerly VC-backed Foster City, CA 00000 00.000 000000000 00.000
00000000 Venture Capital-Backed Boston, MA 00 0000 00000000000 0000
000 000000000000 Venture Capital-Backed Barcelona, Spain 00 0000 0000000000 0 0000
0000000 000000 Venture Capital-Backed Stockholm, Sweden 0 000.00 0000000000 0 000.00
You’re viewing 5 of 7 competitors. Get the full list »

ABL Bio Patents

  • 43

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 3

    Granted

  • 6

    Pending

  • 000

    Expiring in next 12 mo

ABL Bio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210024638-A1 Anti-egfr/anti-4-1bb bispecific antibody and use thereof Pending 26-Jul-2019 000000000
US-20210024650-A1 Anti-her2/anti-4-1bb bispecific antibody and use thereof Pending 26-Jul-2019 000000000
AU-2019386549-A1 Anti-4-1bb antibody and use thereof Pending 30-Nov-2018 00000000000
AU-2019390274-A1 Anti-pd-l1/anti-4-1bb bispecific antibodies and uses thereof Pending 30-Nov-2018 00000000000
CA-3121562-A1 Anti-pd-l1/anti-4-1bb bispecific antibodies and uses thereof Pending 30-Nov-2018 C07K16/2878
To view ABL Bio’s complete patent history, request access »

ABL Bio Executive Team (4)

Name Title Board Seat Contact Info
Sang Lee Ph.D Chief Executive Officer & Founder
Jaecheon Lee Chief Financial Officer & Vice President
Bryan Kang Executive
Weon-Kyoo You Ph.D Head, Research & Development and Vice President
To view ABL Bio’s complete executive team members history, request access »

ABL Bio Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial